

SK Bioscience accelerates global growth strategy by picking talent from Big Pharma

23 January 2023 | News

Appoints new leaders to accelerate new growth strategies

South Korea-based SK bioscience has announced that Richard Kensinger, PhD (Left), former Director and Head of Drug Substance Process Development in Sanofi Pasteur and former Executive Director of Process Development and Protein Sciences at Affinivax Inc. has joined in 'SK bioscience USA Inc.' as Vice President of R&D Project Management.

Dr Kensinger is an expert who has been dedicated to biopharmaceutical R&D, working at global companies for more than 20 years. He received a Bachelor of Science in Health Sciences at Eastern University and a PhD in Biochemistry and Molecular Biology at the Pennsylvania State University.

Dr Kensinger as an expert of R&D process, will take a role in strengthening the company's global competitiveness mainly targeting the United States market by improving the manufacturing process to the cGMP (Good Manufacturing Practice) level, the US certification for manufacturing practice which is considered as the highest standard worldwide.

SK bioscience has additionally recruited Kenneth Lee (right), former Head of Commercial Division, Americas of GenScript Probio, as Vice President of Biologic Business Development Department at R&D Centre in Pangyo, South Korea.

Starting at Gilead Sciences, Inc., Lee worked at various Korean and international biopharmaceutical companies such as CrystalGenomics Inc., BioMarin Pharmaceutical Inc., Binex Co., and Samsung Bioepis, managing R&D, business development, M&A, etc.

Lee will be in charge of developing new biopharmaceutical-driven strategies beyond the vaccine business including a Cellular & Gene Therapy (CGT) field.